Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ConvaTec ( (GB:CTEC) ) has provided an announcement.
Convatec Group has published its Annual Report and Accounts for the financial year ended 31 December 2025 on its corporate website, with printed copies to be mailed to shareholders who have opted for paper communications. The report has also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism, ensuring regulatory compliance and providing public access for investors and other stakeholders.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £360.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Neutral.
The score is driven primarily by solid underlying financial performance (growth, improving operating margins, positive free cash flow) and supportive guidance for continued growth and margin expansion. This is tempered by increased leverage and notable operational/regulatory risks flagged on the call, while valuation looks expensive and technicals appear near overbought despite an uptrend.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec Group is a global medical products and technologies company focused on managing chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. Operating in around 90 countries with over 10,000 employees, it generates more than $2 billion in annual revenue and is a constituent of the FTSE 100 Index under the ticker CTEC.
Average Trading Volume: 8,025,784
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.65B
Find detailed analytics on CTEC stock on TipRanks’ Stock Analysis page.